Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2008

View Archived Issues

Recombinant BDNF fusion protein protects against Abeta-induced learning deficits

Positive preclinical results of new dengue virus vaccine candidates

Positive immunological data reported for ATX-MS-1467 in multiple sclerosis

PHOENIX 1 results show long-term efficacy of ustekinumab in psoriasis

Novel panErbB kinase inhibitor with potential against intracranial tumors profiled

Beta-blocker nadolol well tolerated and beneficial in asthma patients

Amgen and Takeda enter collaboration in Japan on up to 13 Amgen candidates

New treatments for arthritis and other inflammatory disorders disclosed in recent patent literature

Novel analgesic agents imparted in recent patents

New therapeutic agents for diabetes described in recent patents

Novel atypical antipsychotic drug profiled at Neurosearch

Biovitrum initiates process to move focus to specialist care diseases

SciClone initiates phase II trial of RP-101 in late-stage pancreatic cancer

Ziopharm initiates dosing in phase I/II studies of indibulin and palifosfamide

Solbec's Coramsine treatment discontinued in renal cell carcinoma patient

Biogen Idec submits IND application for BIIB-015

Advanced Cell Technology completes pre-IND meeting with FDA for RPE cell therapy

Alchemia reaches agreement with FDA to initiate clinical trial of HyCAMP

Progen executes definitive agreement to acquire CellGate

The FDA has accepted for review Centocor's BLA for ustekinumab for plaque psoriasis

Seaside awards USD 4.5 million collaborative research contract to Vanderbilt University

Zydus Cadila enters into collaborations with Prolong and Karo Bio

ActivBiotics receives orphan drug designation from the EMEA for M-40403

Alexza initiates AZ-007 phase I clinical trial

Dosing completed in first cohort in formal pharmacokinetic study for Zenvia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...